A pilot comparison study of four clinician-rated atopic dermatitis severity scales

British Journal of Dermatology

Volumn 173, Issue 2, 2015, Pages 488-497

  Zhao, C Y ^a,b   Tran, A Q T ^a,b   Lazo Dizon, J P ^a,b   Kim, J ^a,b   Daniel, B S ^a,b   Venugopal, S S ^a,b   Rhodes, L M ^a,b   Law, M G ^c   Murrell, D F ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; CHILD; CLINICAL ARTICLE; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY ASSESSMENT; ECZEMA AREA AND SEVERITY INDEX; EXPLORATORY RESEARCH; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTERRATER RELIABILITY; INTRARATER RELIABILITY; MALE; OBJECTIVE SCORING ATOPIC DERMATITIS; OUTCOME ASSESSMENT; PATIENT ORIENTATED ECZEMA MEASUREMENT; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE ASSESSMENT; SIX AREA SIX SIGN ATOPIC DERMATITIS; SKIN DISEASE ASSESSMENT; SKINDEX 29; THREE ITEM SEVERITY INDEX; COMPARATIVE STUDY; CONTROLLED STUDY; DERMATITIS, ATOPIC; DERMATOLOGY; FEASIBILITY STUDY; OBSERVER VARIATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEVERITY OF ILLNESS INDEX; STANDARDS;

ADOLESCENT; DERMATITIS, ATOPIC; DERMATOLOGY; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; OBSERVER VARIATION; PROSPECTIVE STUDIES; QUALITY OF LIFE; SELF REPORT; SEVERITY OF ILLNESS INDEX;

EID: 84941172532     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13846     Document Type: Article

References (35)

1. Schmitt J, Spuls P, Boers M, et al,. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 2012; 67: 1111-17.
2. Schmitt J, Williams H,. Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany. Br J Dermatol 2010; 163: 1166-8.
3. Chalmers JR, Schmitt J, Apfelbacher C, et al,. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol 2014; 171: 1318-25.
4. Vourc'h-Jourdain M, Barbarot S, Taïeb A, et al,. Patient-oriented SCORAD: a self-assessment score in atopic dermatitis. A preliminary feasibility study. Dermatology 2009; 218: 246-51.
5. Verwimp JJ, Bindels JG, Barents M, Heymans HS,. Symptomatology and growth in infants with cow's milk protein intolerance using two different whey-protein hydrolysate based formulas in a Primary Health Care setting. Eur J Clin Nutr 1995; 49 (Suppl. 1): S39-48.
6. Sugarman JL, Fluhr JW, Fowler AJ, et al,. The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol 2003; 139: 1417-22.
7. Silny W, Czarnecka-Operacz M, Silny P,. The new scoring system for evaluation of skin inflammation extent and severity in patients with atopic dermatitis. Acta Dermatovenerol Croat 2005; 13: 219-24.
8. Murao Y, Mae H, Konishi T, et al,. Semiquantitative scoring in children under treatment for atopic dermatitis. Pediatr Int 2004; 46: 330-6.
9. Housman TS, Patel MJ, Camacho F, et al,. Use of the Self-Adminis-tered Eczema Area and Severity Index by parent caregivers: results of a validation study. Br J Dermatol 2002; 147: 1192-8.
10. Costa C, Rilliet A, Nicolet M, Saurat JH,. Scoring atopic dermatitis: the simpler the better? Acta Derm Venereol 1989; 69: 41-5.
11. Charman D, Varigos G, Horne DJ, Oberklaid F,. The development of a practical and reliable assessment measure for atopic dermatitis (ADAM). J Outcome Meas 1999; 3: 21-34.
12. Carel K, Bratton DL, Miyazawa N, et al,. The Atopic Dermatitis Quickscore (ADQ): validation of a new parent-administered atopic dermatitis scoring tool. Ann Allergy Asthma Immunol 2008; 101: 500-7.
13. Schmitt J, Langan S, Deckert S, et al,. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013; 132: 1337-47.
14. Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol 1999; 79: 356-9.
15. Stalder JF, Taïeb A,. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23-31.
16. Barbier N, Paul C, Luger T, et al,. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004; 150: 96-102.
17. Berth-Jones J,. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996; 135 (Suppl. 48): 25-30.
18. Charman CR, Venn AJ, Williams HC,. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004; 140: 1513-19.
19. Schram ME, Spuls PI, Leeflang MM, et al,. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99-106.
20. Bahmer FA,. ADASI score: atopic dermatitis area and severity index. Acta Derm Venereol Suppl (Stockh) 1992; 176: 32-3.
21. Kunz B, Oranje AP, Labreze L, et al,. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195: 10-19.
22. Rullo VE, Segato A, Kirsh A, Sole D,. Severity scoring of atopic dermatitis: a comparison of two scoring systems. Allergol Immunopathol (Madr) 2008; 36: 205-11.
23. Hanifin JM, Thurston M, Omoto M, et al,. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
24. Schmitt J, Spuls PI, Thomas KS, et al,. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol 2014; 134: 800-7.
25. Lewis-Jones MS, Finlay AY, Dykes PJ,. The infants' dermatitis quality of life index. Br J Dermatol 2001; 144: 104-10.
26. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
27. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ,. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-40.
28. Charman CR, Venn AJ, Williams HC,. Reliability testing of the Six Area, Six Sign Atopic Dermatitis severity score. Br J Dermatol 2002; 146: 1057-60.
29. Charman CR, Venn AJ, Ravenscroft JC, Williams HC,. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326-32.
30. Mokkink L, Terwee C, Patrick D, et al,. COSMIN Checklist Manual. Amsterdam: VU University Medical Center, 2009.
31. Walter SD, Eliasziw M, Donner A,. Sample size and optimal designs for reliability studies. Stat Med 1998; 17: 101-10.
32. Ramsay B, Lawrence CM,. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991; 124: 565-70.
33. Tabolli S, Pagliarello C, Paradisi A, et al,. Burden of disease during quiescent periods in patients with pemphigus. Br J Dermatol 2014; 170: 1087-91.
34. Albrecht J, Taylor L, Berlin JA, et al,. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-94.
35. Rosenbach M, Murrell DF, Bystryn JC, et al,. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 2009; 129: 2404-10.